AzTrials
AzTrials

Cognitive ChangeNCT05546424

EMRESERVA to Enhance Cognitive Reserve in Multiple Sclerosis

An observational study of Cognitive Change, run by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla at 1 site in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Multiple Sclerosis(MS) is an immunological degenerative disease that affects central nervous system causing cognitive impairment, which is one of the most disabling symptoms in MS. Read more about this study

Who is it for?
Ages 18 to 55 years
Conditions the study is for
Cognitive Change
What is being tested?
EMRESERVA
How many people
58 participants
Where
1 siteSpain
Study dates
19 May 2022to 30 Nov 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • No healthy volunteers
  • Adult

Study population: Patients under follow-up in the Multiple Sclerosis unit, diagnosed with RRMS (according to the revised McDonald 2017 criteria) and without cognitive impairment will be selected. The presence or absence of cognitive impairment will be determined according to Amato´s criteria, and defined as the absence of a failure on at least two BRB-N tests, with scores of at least 1.5 SD below the scores of healthy controls

Who may be able to join

  • Aged 18-55 years (both inclusive).
  • Relapsing-remitting Multiple Sclerosis (RRMS) according to the 2017 McDonald Revised Criteria with less than 15 years of evolution.
  • Patients with EDSS <3
  • No cognitive impairment on the Brief Neuropsychological Battery of Rao (BRB-N) (Form A) corrected for age and education performed on the last three months in the MS Unit of Hospital Virgen Macarena (UEMAC) according to Amato´s criteria
  • Able to attend group sessions.
  • Patients able to give written Informed Consent.

Who cannot join

  • Diagnosis of Secondary Progressive or Primary Progressive MS according to McDonald revised criteria (2017)
  • No evidence of relapse or corticosteroid treatment in the 3 months prior to study inclusion.
  • Had vision or hearing problems, such that they were unable to complete the cognitive assessments.
  • Had concurrent severe medical or psychiatric conditions, which prevented them from engaging in treatment and/or Beck Depression Inventory > 20.
  • Involved in other psychological intervention trials.

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • Fundación Pública Andaluza para la gestión de la Investigación en Salud de Sevilla (FISEVI)

    Seville, Andalusia, 41013

Other trials in Spain

About this study

Official title: EMRESERVA A Program to Enhace Cognitive Reserve in Patients With Multiple Scleorisis

Multiple Sclerosis(MS) is an immunological degenerative disease that affects central nervous system causing cognitive impairment, which is one of the most disabling symptoms in MS. Cognitive reserve may influence manifestations of symptoms of cognitive impairment in MS patients and could justify interindividual differences. Cognitive reserve hypothesis raises that enriching life experiences creates a higher capacity and efficiency of neural networks and protects against cognitive decline in neurological diseases.

Scientific evidence demonstrates that older adults with a higher educational,occupational attainment or engagement in cognitively stimulating leisure activities have a reduced risk of dementia.Systematic reviews report little efficacy of pharmacological and behavioral treatments impairment in cognitive functions in MS patients . As such, best treatment of cognitive impairment in MS may be a proactive prevention of cognitive decline in first place Through the application of the EM-Reserva program our goal is to evaluate if it is possible to improve cognitive skills of patients with MS without cognitive impairment versus those who undergo non-specific cognitive exercises. In the short and medium term, EM-Reserva program could improve cognitive performance and delay the appearance or modulate the severity of cognitive impairment in the course of the disease

Read the detailed description

The cognitive profile is homogeneous in MS. This neuropsychological profile is characterised by impairment of memory ,speed of information processing, attention and executive functions. Periodic cognitive explorations are necessary to assess evolution of patients with MS. This evaluation helps to establish a neuropsychological profile which could help to study cognitive and emotional symptoms of MS. Therefore, using reliable cognitive tests could enable to study neuropsychological disorders associated with MS.

Impact of cognitive impairment on daily routine of people with MS can be diverse and is one of major causes of disability in MS. Therefore is vital to stablished which is the role of cognitive and brain reserve and if they could explain inconsistency between structural damage and cognitive functions in MS.

Attention, information processing speed, working memory, and verbal fluency have a positive impact in cognitive reserve. Therefore, our goal is to assess whether EM-Reserva specific cognitive program have a positive impact in these cognitive functions and maybe could prevent onset of cognitive impairment.

According to Sumowski and Leavitt three activities have a strong association with enhancement of cognitive reserve.

  1. Cognitive leisure tasks These activities are 1) reading books, 2) reading magazines or newspapers, 3) producing art (for example, painting, poetry or sculpture), 4) writing non-art productions (for example, a newspaper or a blog), 5) playing a musical instrument, 6) playing structured games (for example, cards, board games, crossword puzzles) and 7) engaging in hobbies (for example, gardening, model building and web design).
  2. Aerobical physical exercises
  3. Activities that promote social relationships.Gatz and Sumowskihighlighted that the establishment of complex cognitive activities in daily life may be relevant in order to achieve a positive impact in cognitive reserve and delay the onset of cognitive symptoms.

Therefore, is proposed to evaluate cognitive impact of the "EMReserva" specific cognitive training to maintain or improve cognitive functions in patients with MS compared to a standard cognitive training. A five-month (20 weeks) intervention program is proposed to evaluate efficacy of cognitive training programs in patients with MS. Cognitive performance improvement has been found after 5-15 weeks (28-32) of cognitive training. On the other hand, musical techniques had been used in cognitive rehabilitation for 24-36 weeks (33-36)

OBJECTIVES(enter elsewhere) METHODS(enter elsewhere) This is a pragmatic, unicentric, observer-blinded Randomized Controlled Trial (RCT) comparing cognitive rehabilitation programme EM-Reserva (intervention) with usual cognitive care alone(control).

This trial will be conducted in Multiple Sclerosis Unit of Virgen Macarena Universitary Hospital (UEMAC) in Seville, Spain.

Neuropsychologists will check participants' availability to attend groups. Groups of 6 participants who could potentially attend for treatment at the same time and venue were individually randomized to either "EM-Reserva'' intervention or usual cognitive care on a 1:1 ratio. Allocation will be stratified by results of Cognitive Reserve Questionnaire.

Normative data of the CRC were determined using quartiles. In this way, a score equal to or less than 6 points, which belongs to quartile 1 (≤ C1), would place the subject's degree of cognitive reserve in the lower range. Between 7 and 9 points (C1-C2) would correspond to a cognitive reserve located in the medium-low range, while between 10 and 14 (C2-C3) would be considered mediumhigh.

Those scores ≥ 15 points would be classified as a cognitive reserve located in the upper category (≥ C4) (23) The allocation algorithm was held on a secure server using an Internet Based randomization system to obtain treatment allocations for each participant and will be stratified taking in account CRC Quartiles in order to avoid a selection bias. Neuropsychologists and participants will be aware of the group allocation. Neurologists will be blinded to group allocation and will perform SDMT (primary endpoint of the study) Non-specific cognitive exercises included general advice from MS neuropsychologist specialists on how to manage cognitive difficulties and general cognitives exercises to improve cognitive performance elaborated at our MS Unit, using exercises like sudokus, crosswords and labyrinths.

This control group will require completion of at least 30 minutes of cognitive exercises daily from Monday to Friday for 5 months. As a complement, patients will be instructed to read newspapers or magazines at least 15 minutes daily.

Specific cognitive rehabilitation program "EM-Reserva" will be provided by two specialized MS Neuropsychologists in groups of 6 participants who will meet approximately an hour weekly, for 5 months. "EM reserva" cognitive program includes the following activities:

  1. Cognitive leisure tasks 1) Reading books. 2) Reading magazines or newspapers daily. 3) Creative tasks type "Zentagle" drawing, 1 production per week. 4) Writing non-artistic productions: Journal writing or summaries of weekly activities will be recommended. 5) Playing a musical instrument: weekly group piano lessons will be held with a piano keyboard. 6) Playing structured games: Weekly groups will be held to play board games. 7) Participate in socio-cultural activities such as museum visits, exhibitions, etc., once a month.
  2. Physical exercises (workout exercises): Group workout will be carried out through a virtual platform three times a week (one hour per session) assisted by a specialized MS Neurophysioterapist.
  3. Activities that promote social relationships (social exercises): through group piano teaching lessons, board games for groups and other group activities.

The "EM Reserva" cognitive training program will be carried out in groups (up to 6 patients) who will meet one hour once a week for 5 months. In addition, patients will perform 30 minutes of individual cognitive exercises at home from Monday to Friday (musical exercises with piano/reading/writing...) Physical exercises will be done using a virtual platform, conducted by a non-blinded Neurophysioterapist specialized in MS. Attendance and compliance will be recorded in both intervention/control groups. If participants missed a group session, they could attend early for the following session to catch up on the content they had missed.

Compliance with prescribed homework will also be evaluated and recorded. Outcomes assessed at 6 and 12 months after randomization included the SDMT, Brief Repeatable Battery of Neuropsychological Test (BRB-N), Vocabulary WAIS-IV, TMT A/B, WMI WAIS-IV, Tower of London test, phonetic and semantic fluencies (COWAT), MSQOL-54, BDI and BAI and PDQ-5.

Questionnaires will be administered by specialized MS Neuropsychologists. EDSS, number of relapses, number of new/enlarged T2 lesions on cerebral MRI and concomitant medications will also be recorded. This information will be collected by specialized MS Neurologists blinded to intervention (visit 0 and visit 12 months).

Study Assessments A specific Cognitive Battery of recognized validity and reliability in this type of patients is used for this purpose. Patients will perform Brief Repeatable Neuropsychological Test Battery for MS (BRB-N), which evaluates verbal and visual memory, attention, information processing speed and prefrontal functions.Other test such as buschke Selective Reminder test (SRT), 10/36 Spatial recall Test (10/36 SRT),Symbol Digit Modalities Test (SDMT), Paced Auditory serial addition task (PASAT) and Verbal fluency test (FV) and Trail Making Test A-B (TMT A-B) will be also perform.

To asses executive functions other tests will be used, such as Working Memory Index test (WAIS-IV),Tower of London,Controlled Oral Word Association Test (COWAT),Wechsler Abbreviated Intelligence Scale, Cognitive Reserve Questionnaire (CRQ).

In order to evaluate the effect of the programme quality of life test all patients will perform Multiple Sclerosis International Quality of Life questionnaire (MusiQoL-54) ,PDQ (Perceived Deficit Questionnaire), Modified fatigue impact scale (MFIS-5) and The Beck Depression Inventory (BDI)

WORK PLAN

  1. To select 58 patients who met inclusion/exclusion criteria (VISIT 0). They will be randomized in two groups (Intervention/Control) and stratified taking in account the punctuation in Cognitive Reserve Questionnaire and age, in a randomized 1:1 masked manner.
  2. VISIT 1 (+/- 3m from VISIT 0), evaluate cognitive performance in both groups, using SDMT, (form2), Vocabulary WAIS-IV, TMT A/B, WMI WAIS-IV, TLT, Tower of London test, phonetic and semantic fluencies (COWAT).Administer MSQOL-54, BDI and BAI and PDQ-5 tests.
  3. VISIT 2 (6 m +/- 1 month) evaluate cognitive performance in both groups, using SDMT(Form 3), BRB-N (Form B) , Vocabulary WAIS-IV, TMT A/B, WMI WAIS-IV, TLT, Tower of London test, phonetic and semantic fluencies (COWAT). Administer MSQOL-54, BDI and BAI and PDQ-5 tests.
  4. VISIT 3(12 m +/- 1 month) evaluate cognitive performance in both groups with SDMT (Form 1), BRB-N (Form A) , Wechsler Intelligence Scale Vocabulary subtest (WAIS IV), TMT A-B, work memory index (WAIS), Tower of London test, phonetic and semantic fluencies, and MSQOL-54.
  • Differences in neuropsychological tests before and after cognitive rehabilitation will be evaluated by ANOVA two-factors with replication adn Wilks' Lambda test to test the hypothesis of equality.

Each test performance will be adjusted by age, education, and gender.

  • Clinical/demographic data will be assessed in visit 0, visit 2 and visit 3, including sex, age, time of MS evolution, number of relapses, Kurtzke's Expanded Disability Status Scale (EDSS), number of cerebral magnetic resonance T2 lesions and gadolinium enhanced lesions and if they are receiving any Disease Modifying treatment.

EXPECTED OUTCOMES Intellectual enrichment is associated with greater protective efficiency of manifestations of cognitive dysfunctions.

After administration of EMReserve program, cognitive improvement with enrichment of cognitve reserve is expected. This fact may be reflected in neuropsychological assessment scores of patients who were included in the program whereas measures of patients who undergo non-specific program will not be increased.

Patients who complete the EMReserva program, due to increased cognitive reserve, will be less likely to develop cognitive impairment at one year from baseline.

If the EMReserva program proves to be effective in improving cognitive capacities involved in cognitive reserve, it would be considered necessary to maintain these cognitive habits throughout life. Therefore, the mental, physical and social exercises based on this program would be implemented as part of the global approach to their disease.

The present study aims to invest resources in prevention of cognitive impairment in patients affected by MS given its high prevalence and the impact on their daily life and quality of life as they are a young working population with high mental demands.

Being tested
EMRESERVA

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • EMRESERVABehavioural

    training program will be carried out in groups (up to 6 patients) who will meet one hour once a week for 5 months.

Study groups in NCT05546424
Study groupRoleWhat they receive
controlNon-specific cognitive exercises included general advice from MS neuropsychologist specialists on how to manage cognitive difficulties and general cognitives exercises to improve cognitive performance elaborated at our MS Unit, using exercises like sudokus, crosswords and labyrinths. This control group will require the completion of at least 30 minutes of cognitive exercises daily from Monday to Friday for 5 months. As a complement, patients will be instructed to read newspapers or magazines at least 15 minutes daily.
Receives: Behavioral: EMRESERVA
Intervention EMRESERVASpecific cognitive rehabilitation program "EM-Reserva" will be provided by two specialized MS Neuropsychologists in groups of 6 participants who will meet approximately an hour weekly, for 5 months."EM reserva" cognitive program includes the following activities: 1. Cognitive leisure tasks 2. Physical exercises (workout exercises) 3. Activities that promote social relationships (social exercises)
Receives: Behavioral: EMRESERVA

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Symbol Digit modality test

    Change in mean scores. Asociate display symbol to corresponding number. Number of correct responses in 90 seconds

    Measured: at month 6

Secondary outcomes (10)
  1. Change in Trail Making Test form A and B

    change in mean scores

    Measured: at 6 and 12 months.

  2. Change in BRB-N subtest

    Change in mean scores

    Measured: at 6 and 12 months

  3. Change in Wechsler Intelligence Scale Vocabulary subtest (WAIS IV) mean scores at 6 and Change in Wechsler Intelligence Scale Vocabulary subtest (WAIS IV) mean scores at 6 and Change in Wechsler Intelligence Scale Vocabulary subtest

    Change in mean scores

    Measured: at 6 and 12 months

  4. Change in Work memory index (WAIS)

    Change in mean scores

    Measured: at 6 and 12 months

  5. Change in Tower of London test

    Change in mean scores

    Measured: at 6 and 12 months

  6. Change in Phonetic and semantic fluencies

    Change in mean scores

    Measured: at 6 and 12 months

  7. Change in Multiple Sclerosis Quality of Life-54 (MSQOL-54) questionnaire

    Change in mean scores

    Measured: at 6 and 12 months

  8. Change in Beck depression/anxiety questionnaires

    Change in mean scores

    Measured: at 6 and 12 months

  9. Change in MFIS-5

    Change in mean scores

    Measured: at 6 and 12 months

  10. Change in Perceived Deficit Questionnaire (PDQ-5)

    Change in mean scores

    Measured: at 6 and 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Sep 2022
  2. Study start19 May 2022
  3. Primary completion30 Nov 2023
  4. Study completion30 Nov 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
58 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05546424
Sponsor's protocol ID
EMRESERVA
Status last verified
Sep 2023
First submitted
12 May 2022
Last updated
7 Feb 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Amato MP, Zipoli V, Portaccio E. Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies. J Neurol Sci. 2006 Jun 15;245(1-2):41-6. doi: 10.1016/j.jns.2005.08.019. Epub 2006 Apr 27.

    PubMed 16643953
  • Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology. 1991 May;41(5):685-91. doi: 10.1212/wnl.41.5.685.

    PubMed 2027484
  • Benedict RH, Cox D, Thompson LL, Foley F, Weinstock-Guttman B, Munschauer F. Reliable screening for neuropsychological impairment in multiple sclerosis. Mult Scler. 2004 Dec;10(6):675-8. doi: 10.1191/1352458504ms1098oa.

    PubMed 15584493
  • Schwartz CE, Snook E, Quaranto B, Benedict RH, Vollmer T. Cognitive reserve and patient-reported outcomes in multiple sclerosis. Mult Scler. 2013 Jan;19(1):87-105. doi: 10.1177/1352458512444914. Epub 2012 Apr 30.

    PubMed 22546847
  • Scarmeas N, Levy G, Tang MX, Manly J, Stern Y. Influence of leisure activity on the incidence of Alzheimer's disease. Neurology. 2001 Dec 26;57(12):2236-42. doi: 10.1212/wnl.57.12.2236.

    PubMed 11756603
  • Wilson RS, Mendes De Leon CF, Barnes LL, Schneider JA, Bienias JL, Evans DA, Bennett DA. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA. 2002 Feb 13;287(6):742-8. doi: 10.1001/jama.287.6.742.

    PubMed 11851541
  • Verghese J, Lipton RB, Katz MJ, Hall CB, Derby CA, Kuslansky G, Ambrose AF, Sliwinski M, Buschke H. Leisure activities and the risk of dementia in the elderly. N Engl J Med. 2003 Jun 19;348(25):2508-16. doi: 10.1056/NEJMoa022252.

    PubMed 12815136
  • He D, Zhang Y, Dong S, Wang D, Gao X, Zhou H. Pharmacological treatment for memory disorder in multiple sclerosis. Cochrane Database Syst Rev. 2013 Dec 17;2013(12):CD008876. doi: 10.1002/14651858.CD008876.pub3.

    PubMed 24343792
  • Rosti-Otajarvi EM, Hamalainen PI. Neuropsychological rehabilitation for multiple sclerosis. Cochrane Database Syst Rev. 2014 Feb 11;2014(2):CD009131. doi: 10.1002/14651858.CD009131.pub3.

    PubMed 24515630
  • Sumowski JF. Cognitive Reserve as a Useful Concept for Early Intervention Research in Multiple Sclerosis. Front Neurol. 2015 Aug 20;6:176. doi: 10.3389/fneur.2015.00176. eCollection 2015. No abstract available.

    PubMed 26347706
  • Heaton RK, Nelson LM, Thompson DS, Burks JS, Franklin GM. Neuropsychological findings in relapsing-remitting and chronic-progressive multiple sclerosis. J Consult Clin Psychol. 1985 Feb;53(1):103-10. doi: 10.1037//0022-006x.53.1.103. No abstract available.

    PubMed 3980815
  • Potagas C, Giogkaraki E, Koutsis G, Mandellos D, Tsirempolou E, Sfagos C, Vassilopoulos D. Cognitive impairment in different MS subtypes and clinically isolated syndromes. J Neurol Sci. 2008 Apr 15;267(1-2):100-6. doi: 10.1016/j.jns.2007.10.002. Epub 2007 Nov 13.

    PubMed 17997417
  • Arnett P, Forn C. [Neuropsychological evaluation in multiple sclerosis]. Rev Neurol. 2007 Feb 1-15;44(3):166-72. Spanish.

    PubMed 17285522
  • Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008 Dec;7(12):1139-51. doi: 10.1016/S1474-4422(08)70259-X.

    PubMed 19007738
  • Achiron A, Barak Y. Cognitive impairment in probable multiple sclerosis. J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):443-6. doi: 10.1136/jnnp.74.4.443.

    PubMed 12640060

Questions about this trial

What is this clinical trial studying?

An observational study of Cognitive Change, run by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Symbol Digit modality test (time frame: at month 6). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05546424, which also lists 46 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Feb 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in